Full Text View
Tabular View
No Study Results Posted
Related Studies
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
This study has been terminated.
( Company decision to discontinue the AVE1642 development program, not due to any safety or efficacy concerns )
Study NCT00791544   Information provided by Sanofi

First Received on November 13, 2008.   Last Updated on August 3, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Liver Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Hepatocellular
More general conditions related to this trial
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
AVE1642
sorafenib
erlotinib
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Sanofi


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services